Clinical Trials Directory

Trials / Completed

CompletedNCT01490424

TREM-1 Gene Polymorphisms

Association Between TREM-1 Gene Polymorphisms and Prognosis in Sepsis Patient

Status
Completed
Phase
Study type
Observational
Enrollment
160 (actual)
Sponsor
Chinese PLA General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell surface receptor expressed on neutrophils and monocytes. TREM-1 acts to amplify inflammation and serves as a critical mediator of inflammatory response in the context of sepsis. Blocking of TREM-1 can protect against sepsis in mice. This study was designed to investigate whether TREM-1 genomic variations were associated with the prognosis of sepsis. We sequenced 30 sepsis patients with TREM-1 gene of four exons by PCR sequencing. When analyzing the results of sequencing, we found two gene polymorphisms located in exon-2 and exon-4, respectively. Compare with the NCBI dbSNP and Hapmap database, one polymorphisms located in exon-2 is non-synonymous variation rs2234237(Ser25Thr), the other one located in exon-4 is synonymous variation rs2234246. Two common polymorphisms (rs2234237,rs2234246) within the TREM-1 gene were detected in 80 patients with severe sepsis and in 80 healthy control subjects. This study was explored that whether or not polymorphisms detected within the TREM-1 gene may play a major role in the predisposition to prognosis of sepsis in a Chinese Han cohort.

Conditions

Timeline

Start date
2010-05-01
Primary completion
2011-10-01
Completion
2011-10-01
First posted
2011-12-13
Last updated
2011-12-13

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01490424. Inclusion in this directory is not an endorsement.